Learn
FDA Grants Accelerated Approval for as a Breakthrough Treatment for Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) granted accelerated approval for Leqembi (lecanemab-irmb) as a groundbreaking treatment. This marks a pivotal moment in the ongoing battle against Alzheimer's, with Leqembi being the second medication approved for the disease designed to tackle its fundamental pathophysiology.